Semantic Scholar uses AI to extract papers important to this topic.
Recently, the United States Food and Drug Administration approved vigabatrin (Sabril®) for the treatment of adults with… Expand Vigabatrin (Sabril) is an antiepileptic drug indicated for the treatment of partial epilepsy, which is only licensed as first… Expand A 52 year old woman presented with neuropathic pain in both legs. Clinical neurological and neurophysiological examinations… Expand PURPOSE
A case control study was conducted to assess the effect of Sabril (Vigabatrin), Lamictal (Lamotrigine) and Neurontin… Expand Summary: Purpose: Vigabatrin (Sabril, Hoechst Marion Roussel) is an antiepilepsy drug (AED) presently marketed in 64 countries… Expand Purpose: Vigabatrin (Sabril), a drug that blocks GABA transaminase, has been used in the treatment of epilepsy since 1989. There… Expand Summary Vigabatrin (VGB) prevents seizures by irreversible inhibition of γ‐aminobutyric acid (GABA) transaminase and a resulting… Expand Summary: Vigabatrin (VGB, Sabril) is a new antiepileptic drug used for treatment of partial and secondarily generalized tonic… Expand The novel antiepileptic drug vigabatrin (Sabril) acts by inhibiting degradation of the inhibitory neurotransmitter gamma… Expand Ten patients, suffering from drug-resistant complex partial seizures were treated for a period of up to 3 years with vigabatrin… Expand